Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Numerous psychiatric and neurodegenerative diseases like schizophrenia, dependency on drugs of abuse, depression and Parkinson's disease are related to motivational and cognitive deficits in value-based decision making, which frequently persist even after a successful pharmacological treatment. According to current neurobiologic models, cortical dopamine D1 receptors play a crucial role in taking value-based decisions. In this study, it will be investigated whether value-based decisions in healthy volunteers can be improved by stimulation of D1-receptors. For this purpose, a newly developed dopamine D1-agonist will be used, which selectively increases the activities of frontal D1- and D5-receptors. In this double-blind, randomized, placebo-controlled study, the effects of different single doses of PF-06412562, a not yet licensed D1-agonist, on value-based decision making will be compared with placebo. The use of different dosage strengths will allow to investigate a potential relationship between the extent of activity of the D1-receptor and its influence on behavioral indices.
Therefore, four parallel groups will be investigated. Each participant takes in a single dose of either PF-06412562 in different doses or placebo. A screening exam will be carried out 1-3 weeks before the drug intake, and a follow-up examination will be carried out approx. 1 week after the drug intake. At all 3 visits in the study centre, several tests for the investigation of value-based decision making will be carried out.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active dose 1 | Experimental | Single dose of PF-06412562 in low dosage strength |
|
| Active dose 2 | Experimental | Single dose of PF-06412562 in medium dosage strength |
|
| Active dose 3 | Experimental | Single dose of PF-06412562 in higher dosage strength |
|
| Placebo | Placebo Comparator | Single dose of placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-06412562 | Drug | double-blind oral intake of single doses of the aforementioned drug or placebo |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in a delay discounting task. | This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo. | 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake. |
| Change from baseline in a risk discounting task. | This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo. It will be carried out after the test for outcome 1. | 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake. |
| Effect of PF-06412562 on an effort discounting task (compared to placebo). | This validated computer-based decision-making test will be completed by each participant 5 hours after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo and after having completed the tests for outcome 1 and 2. | 5 hours after drug intake. |
| Effect of PF-06412562 on the Pavlovian to instrumental transfer task (compared to placebo). | This validated computer-based decision-making task tests Pavlovian acquisition and transfer. It will be carried out by each participant immediately after the test in outcome 3. | 5 hours after drug intake. |
| Effect of PF-06412562 on an exploration / exploitation task (compared to placebo). | This validated computer-based decision-making task tests different aspects of value-based decision making. It will be carried out by each participant immediately after the test in outcome 4. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of treatment-emergent adverse events (safety and tolerability of PF-06412562) | continuous assessment of adverse events by non-leading questions, repeated safety laboratory tests, repeated ECGs, repeated control of vital parameters. | throughout the study and up to 1 week after study drug intake. |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma concentrations of PF-06412562 | blood sampling 4 hours and 8 hours after the study drug intake. |
Inclusion Criteria:
Informed Consent as documented by signature on the informed consent form
Physically and psychiatrically healthy men and women
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days for females and 90 days for males after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children.
Female subjects of non childbearing potential must meet at least one of the following criteria:
All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.
Aged 18-35 years
Negative pregnancy test (see exclusion criteria)
Normal or corrected-to-normal vision
Exclusion Criteria (selected):
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philippe Tobler, Prof. Dr. | University of Zurich, Dept. of Economics | Study Director |
| Alexander Jetter, MD | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Zurich, Dept. of Clinical Pharmacology and Toxicology | Zurich | CH-8091 | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31668477 | Result | Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN. Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences. Biol Psychiatry. 2020 Apr 1;87(7):678-685. doi: 10.1016/j.biopsych.2019.09.002. Epub 2019 Sep 12. | |
| 31962344 | Result | Soutschek A, Kozak R, de Martinis N, Howe W, Burke CJ, Fehr E, Jetter A, Tobler PN. Activation of D1 receptors affects human reactivity and flexibility to valued cues. Neuropsychopharmacology. 2020 Apr;45(5):780-785. doi: 10.1038/s41386-020-0617-z. Epub 2020 Jan 21. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
double-blind
| Placebo | Drug | double-blind oral intake of single doses of the aforementioned drug or placebo |
|
| 5 hours after drug intake. |
| Effect of PF-06412562 on a probabilistic reversal learning task (compared to placebo). | This validated computer-based decision-making task tests different aspects of value-based decision making. It will be carried out by each participant immediately after the test in outcome 5. | 5 hours after drug intake. |
| 36884013 | Derived | Soutschek A, Tobler PN. A process model account of the role of dopamine in intertemporal choice. Elife. 2023 Mar 8;12:e83734. doi: 10.7554/eLife.83734. |